Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Institute for Neurodegenerative Disorders Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

NCT00456417
View directory record Official record
Conditions
Alzheimers Disease
Interventions
123-I MNI-187 Injection and Imaging Procedures
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00556660
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] AV-151
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 5, 2026, 7:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00870519
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I-123-MNI-168, 123-I MNI-168
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819
View directory record Official record
Conditions
Parkinsonian Syndrome
Interventions
[123I]ß CIT and SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
22 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 5, 2026, 7:59 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

NCT00387075
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I]β-CIT and SPECT imaging, [123I]β-CIT
Procedure · Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 5, 2026, 7:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

NCT00886951
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I123MNI388/I123MNI390
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

PPMI Tau PET Imaging

NCT04906590
View directory record Official record
Conditions
Parkinson Disease
Interventions
[18F] PI-2620
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years to 100 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 5, 2026, 7:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease

NCT00117195
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Syndrome
Interventions
Automated Neuropsychological Assessment Matrix
Device
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
22 Years and older
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease
Interventions
[18F] CFPyPB
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 2 Interventional

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

NCT00129675
View directory record Official record
Conditions
Parkinsonian Syndrome
Interventions
[123I]ß CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC

NCT01268020
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]-FMH3
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 5, 2026, 7:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

NCT00968097
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
123-I MNI-340
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

NCT00439010
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123I] AV 39
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain

NCT00287248
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] IMPY & SPECT Imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 2 Interventional

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

NCT01141023
View directory record Official record
Conditions
Parkinson Disease
Interventions
DaTscan
Drug
Lead sponsor
Ken Marek, MD
Other
Eligibility
30 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 5, 2026, 7:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

NCT00657813
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-330 as a brain SPECT tracer of Beta-Amyloid
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 5, 2026, 7:59 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

NCT01000870
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-513-01
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

NCT00970229
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease
Interventions
[123I]MNI-420
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 2 Interventional

Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

NCT00397696
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I] 5-IA
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 5, 2026, 7:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects

NCT00470925
View directory record Official record
Conditions
Depression
Interventions
123-I MZINT injection and SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 2 Interventional

Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease

NCT00315250
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Syndrome
Interventions
[123I]β-CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
22 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 2 Interventional

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

NCT00096720
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2010 · Synced Oct 5, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

NCT00448799
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123-I] AV-83 Injection and Imaging Procedures
Radiation
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2008 · Synced Oct 5, 2026, 7:59 PM EDT